Mekinist contains Trametinib, which is a targeted cancer medicine. It belongs to the group of medicines called MEK inhibitors. It is usually prescribed for cancers that have a BRAF V600 mutation and is often used together with Dabrafenib for better results.

Mechanism
Trametinib works by blocking a protein called MEK in the MAPK/ERK pathway. This pathway is overactive in cancers with BRAF mutations, making cancer cells grow and spread quickly. By blocking MEK, Trametinib slows down or stops cancer growth.

Uses

• Melanoma (skin cancer) with BRAF V600 mutation

• Non-small cell lung cancer (NSCLC) with BRAF V600 mutation

• Thyroid cancer with BRAF mutation

• Sometimes used in combination with Dabrafenib for stronger effect

  Adverse Effects
  Common side effects:

  • Fever and chills

  • Tiredness or weakness

  • Nausea, vomiting, diarrhea

  • Rash, dry skin, acne-like changes

  • Swelling in legs or arms

  • Loss of appetite